Probi AB (publ)

Stockholm Stock Exchange PROB.ST

Probi AB (publ) Operating Income Margin for the year ending December 31, 2023: 1.80%

Probi AB (publ) Operating Income Margin is 1.80% for the year ending December 31, 2023, a -77.95% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.

Probi AB (publ) Operating Income Margin for the year ending December 31, 2022 was 8.18%, a -50.72% change year over year.
Probi AB (publ) Operating Income Margin for the year ending December 31, 2021 was 16.60%, a -3.76% change year over year.
Probi AB (publ) Operating Income Margin for the year ending December 31, 2020 was 17.25%, a -3.18% change year over year.
Probi AB (publ) Operating Income Margin for the year ending December 31, 2019 was 17.81%, a 6.42% change year over year.

Key data

Date	Operating Income Margin	EBT Margin	Net Income Margin	EBITDA Margin

Stockholm Stock Exchange: PROB.ST

Probi AB (publ)

CEO	Ms. Anita Johansen
IPO Date	Dec. 2, 2004
Location	Sweden
Headquarters	Ideongatan 1A
Employees	157
Sector	Consumers Staples
Industries Non-Alcoholic Beverages Alcoholic Beverages Biotechnology Cosmetics Food & Beverages Pharmaceuticals Soft Drinks & Sodas Vaccines

Description

Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.

Key trends

Past 5 years